Search the Newsreel

argenx SE: argenx Announces Commencement of Tender Offer to Acquire Forte Biosciences, Inc.

argenx SE announced the commencement of a tender offer to acquire all outstanding shares of Forte Biosciences, Inc. for $77.00 per share in cash. This acquisition will make Forte Biosciences a wholly-owned subsidiary of argenx. Forte's Board of Directors has recommended that shareholders accept …

Bank of America Corp DE Boosts Stake in Banco Bilbao Viscaya Argentaria S.A. $BBVA

Emergent BioSolutions Inc. 2026: Revenue $234.3M, EPS ($3.49) — 10-Q Summary

Emergent BioSolutions Inc. reported its second-quarter 2026 results, with revenue increasing to $234.3M from $140.9M year-over-year. Despite this growth, the company recorded a net loss of ($180.2M) and diluted EPS of ($3.49), primarily due to a $191M non-cash impairment on NARCAN® intangible assets. The …

Argent BioPharma (ASX:RGT): Why Does Cannepil Development Pathway Matter?

BioLife Solutions (NASDAQ: BLFS) plans cash-stock merger with Repligen

Loma Negra Compania Industrial Argentina (LOMA) Earnings Date and Reports 2026

Emergent BioSolutions (NYSE: EBS) posts Q2 loss, plans cost-cutting

argenx (ENXTBR:ARGX) After Its Zacks Upgrade What Does The Valuation Narrative Say

Argent BioPharma Advances CannEpil into U.S. Veterinary Market with New Development Program

Is Emergent BioSolutions Inc (EBS) Overvalued After Q2 Earnings

Emergent BioSolutions Inc. 2026 Q2 - Results - Earnings Call Presentation (NYSE:EBS) 2026-08-05

Key Points Interested in Emergent Biosolutions Inc.? Here are five stocks we like better. Q2 performance exceeded expectations: Revenue reached $234 million and adjusted EBITDA rose to $97 million, driven by accelerated medical countermeasure deliveries and strong U.S. government contract activity. NARCAN competition is …

Emergent BioSolutions Reports Second Quarter 2026 Financial Results

Emergent BioSolutions announced its second-quarter 2026 financial results, reporting total revenues of $234.3 million, a 66% increase year-over-year, and an adjusted net income of $30.9 million, up 134%. Despite a significant net loss due to a non-cash impairment charge, the company is implementing a …

Narcan maker Emergent BioSolutions eliminates top R&D role in sweeping restructuring

Emergent BioSolutions is undergoing a significant restructuring, including laying off 93 employees, eliminating the chief medical officer and head of R&D role, and closing two labs. These changes, aimed at saving $40 million annually, are a response to increased competition in the naloxone market, …

Emergent records $191.3M non-cash charge related to NARCAN asset group

Emergent BioSolutions reported Q2 2026 total revenues of $234.3 million, a 66% increase year-over-year, driven primarily by higher U.S. government sales of smallpox and other medical countermeasure products. Despite this revenue growth and improved adjusted net income and EBITDA, the company posted a GAAP …

California State Teachers Retirement System Raises Holdings in Repligen Corporation $RGEN

The California State Teachers Retirement System increased its stake in Repligen Corporation (NASDAQ:RGEN) by 22.1% in the first quarter, now holding 61,860 shares valued at $7.3 million. Repligen exceeded analyst expectations with quarterly revenue of $204.13 million and earnings of $0.54 per share, and …

Emergent BioSolutions Commits to Cross-Sector Collaboration Against Biological Threats in an Evolving Global Security Environment

Emergent BioSolutions (NYSE: EBS) emphasizes the critical need for cross-sector collaboration to address evolving biological threats stemming from geopolitical conflicts, AI, and synthetic biology. The company highlights calls from European health officials and AI industry leaders for stronger safeguards and points to recent anthrax-related …

Telecom Argentina SA Class B Revenue Breakdown – BCBA:TECO2

Telecom Argentina SA Class B (BCBA:TECO2) generated 8.33 trillion ARS last year, with its Information and Communications Technology Services segment contributing 5.28 trillion ARS. The majority of the company's revenue, 8.03 trillion ARS, originated from Argentina.

Lithium Argentina Closes $220M Debt Facilities | LAR Stock News

Lithium Argentina (LAR) has secured $220 million in new unsecured debt facilities for its Cauchari-Olaroz lithium brine operation, aimed at funding a Stage 2 expansion to add 45,000 tonnes per annum of lithium carbonate equivalent production. The financing includes a $50 million two-year facility …

Lithium Argentina Announces $220 Million of New Debt Facilities Closed at Cauchari-Olaroz

Lithium Argentina announced the closing of $220 million in new unsecured debt facilities for its Cauchari-Olaroz lithium brine operation. These facilities, consisting of a $50 million and a $170 million credit line, will strengthen the company's financial position and provide funding flexibility for its …

Moody National Bank Trust Division Makes New Investment in Repligen Corporation $RGEN

Moody National Bank Trust Division has acquired a new stake in Repligen Corporation (NASDAQ:RGEN), purchasing 17,728 shares valued at approximately $2.42 million. This investment comes as institutional investors collectively own 97.64% of the biotechnology company. Repligen recently reported strong quarterly earnings, exceeding analyst expectations …

Emergent Biosolutions: Q2 Earnings Snapshot

Earnings call transcript: Emergent BioSolutions Q2 2026 revenue tops guidance

This article provides the Q2 2026 earnings report for Emergent BioSolutions. It is a quarterly filing (10-Q) that details the company's financial performance during the second quarter of 2026.

argenx SE (ARGX) Gewinnprognose: Zukünftige EPS & Umsatzwachstumsprognosen

Emergent Biosolutions (NYSE:EBS) Announces Quarterly Earnings Results

Banco Bilbao Vizcaya Argentaria SA (BBVA) Gewinnprognose: Zukünftige EPS & Umsatzwachstumsprognosen

(BBVA) as a Liquidity Pulse for Institutional Tactics

This article provides an AI-driven analysis of Banco Bilbao Vizcaya Argentaria S.a. (NASDAQ: BBVA), highlighting strong sentiment across all time horizons and compelling upside potential due to the absence of resistance levels above the current price. It outlines specific institutional trading strategies, including long, …

Price to earnings forward of Argent Biopharma Ltd – ASX:RGT

Ternium Argentina S.A. presenta sus resultados del segundo trimestre y del primer semestre de 2026

Telecom Argentina Stet - France Telecom (TEO) to Release Earnings on Tuesday

What Makes Argenx (ARGX) a New Buy Stock

Investors might want to bet on argenex SE (ARGX), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. …

Argenx SE (ARGX) Prepares to Demonstrate Vyvgart’s Efficacy in Broader Autoimmune Diseases

Baron Capital, an investment management company, released its Q2 2026 investor letter for the "Baron Health Care Fund". A copy of the letter is available to download here. The Fund gained 11.99% during the quarter, compared with the 10.48% gain for the Russell 3000 …

BBVA Closes EUR1.5 Billion Share Buyback Tranche

BBVA has successfully completed a share buyback program totaling EUR1.5 billion. This action is part of the bank's strategy to return capital to shareholders. The buyback involved the acquisition of a significant number of shares, which are expected to be cancelled.

Certain Class B Common Stock of Forgent Power Solutions, Inc. are subject to a Lock-Up Agreement Ending on 4-AUG-2026.

Certain Class B Common Stock of Forgent Power Solutions, Inc. will be subject to a lock-up agreement ending on August 4, 2026. This lock-up period, lasting 181 days, prevents company officers, directors, and Continuing Equity Owners from selling or otherwise disposing of these shares …

Repligen Corporation (BLFS) sets cash and stock terms for BioLife Solutions buyout

Repligen Corporation has announced an agreement to acquire BioLife Solutions for a combination of cash and stock. BioLife shareholders will receive $11.25 in cash plus 0.1442 shares of Repligen common stock for each BioLife share. The transaction, described as a strategic combination in the …

Jefferies eleva el precio objetivo de BBVA y su previsión de beneficios hasta 2028

Emergent BioSolutions Inc expected to post earnings of 11 cents a share - Earnings Preview

Emergent BioSolutions Inc. (EBS) is expected to announce earnings of 11 cents per share. This information comes from a Refinitiv earnings preview. The full article is available through TradingView News, which offers access to Reuters and other news sources.